CoChat

Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study

Open access
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., Perahia, D. · 2010 · International Journal of Clinical Practice
Cited by 11

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess the efficacy of duloxetine 60 mg/day in the prevention of depressive recurrence in patients with major depressive disorder (MDD). METHODS: Patients having at least three episodes of MDD in the past 5 years received open-label (OL) duloxetine 60-120 mg/day for up to 34 weeks. Patients meeting response criteria were then randomised to either duloxetine or placebo for up to 52 weeks of double-blind maintenance treatment. Only patients taking duloxetine 60 mg/day during the OL phase, and randomised to either duloxetine (remained on 60 mg/day dose) or placebo, were included in this post hoc analysis. The primary outcome measure was time to recurrence of a major depressive episode. The 17-item Hamilton Rating Scale for Depression (HAMD(17)) was used to evaluate depressive symptomatology. Global and physical functioning and pain were also assessed. Safety and tolerability were assessed via analysis of treatment-emergent adverse events (TEAEs), vital signs and weight. RESULTS: A total of 124 patients were randomised to duloxetine 60 mg/day (n = 64) or placebo (n = 60). Time to depressive recurrence was significantly longer in duloxetine-treated patients compared with placebo-treated patients (p = 0.001). During the double-blind maintenance phase, 31.7% of placebo-treated patients experienced a depressive recurrence compared with 12.5% of duloxetine-treated patients (p = 0.004). The HAMD(17) total score and most of its subscales as well as the Clinical Global Impression of Severity (CGI-S), significantly worsened in the placebo group compared with the duloxetine 60 mg/day group. There were no significant differences between treatment groups in TEAEs, discontinuations because of adverse events, vital signs or weight. CONCLUSIONS: Treatment with duloxetine 60 mg/day was associated with a longer time to depressive recurrence and a significantly lower recurrence rate compared with placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-1241.2010.02374.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 17

  1. Franchini, 1998, Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study, J Clin Psychiatry, 59, 229, 10.4088/JCP.v59n0504 · DOI · Paper page
  2. Gilaberte, 2001, Fluoxetine in the prevention of depressive recurrences: a double-blind study, J Clin Psychopharmacol, 21, 417, 10.1097/00004714-200108000-00009 · DOI · Paper page
  3. Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  4. Guy, 1976, ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM), 76
  5. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, 22
  6. Faries, 2000, The responsiveness of the Hamilton Depression Rating Scale, J Psychiatr Res, 34, 3, 10.1016/S0022-3956(99)00037-0 · DOI · Paper page
  7. DeLoach, 1998, The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale, Anesth Analg, 86, 102
  8. Gahimer, 2007, A retrospective pooled analysis of duloxetine safety in 23,983 subjects, Curr Med Res Opin, 23, 175, 10.1185/030079906X162719 · DOI · Paper page
  9. Davidson, 2008, Duloxetine treatment for relapse prevention in adults with generalised anxiety disorder: a double-blind placebo-controlled trial, Eur Neuropsychopharmacol, 18, 673, 10.1016/j.euroneuro.2008.05.002 · DOI · Paper page
  10. Wernicke, 2007, An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies, Drug Saf, 30, 437, 10.2165/00002018-200730050-00007 · DOI
  11. Wernicke, 2009, Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions, J Diabetes Complications, 23, 349, 10.1016/j.jdiacomp.2008.07.004 · DOI
  12. Berken, 1984, Weight gain. A side-effect of tricyclic antidepressants, J Affect Disord, 7, 133, 10.1016/0165-0327(84)90031-4 · DOI · Paper page
  13. Fava, 2000, Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment, J Clin Psychiatry, 61, 863, 10.4088/JCP.v61n1109 · DOI · Paper page
  14. Wise, 2006, Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical trials, Prim Care Companion J Clin Psychiatry, 8, 269, 10.4088/PCC.v08n0503 · DOI · Paper page
  15. Bech, 2006, Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder, Psychopharmacology, 188, 273, 10.1007/s00213-006-0505-1 · DOI
  16. Lobo, 2009, Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation, Clin Pharmacokinet, 48, 189, 10.2165/00003088-200948030-00005 · DOI
  17. Sharma, 2000, Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor, J Clin Pharmacol, 40, 161, 10.1177/00912700022008810 · DOI · Paper page

Cited by

See all 11

Metadata

Authors
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D.
Venue
International Journal of Clinical Practice
Published
2010-05
Volume
64
Issue
6
Pages
719-726
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
OpenAlex
W2010267403
Cited by
11
References
9
FWCI
1.23
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1949 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study. https://app.cochat.ai/papers/10.1111/j.1742-1241.2010.02374.x
The paper
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010). Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2010.02374.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.